Drug Trial Radar · NCT01863186
Efficacy, Safety and Dose-Response Study Followed by Open-Label Study of Lofexidine Treatment of Opioid Withdrawal
Last checked: Nov 20, 2026Latest source record: Mar 22, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
603
Actual
Start
Jun 2013
Primary completion
Nov 2014
Study completion Dec 2014
Sponsor
- Lead sponsor
- USWM, LLC (dba US WorldMeds)Industry
- Sponsor type
- Industry
- Collaborators
- National Institute on Drug Abuse (NIDA)
- First posted
- May 27, 2013
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to look at the efficacy and safety for lofexidine hydrochloride, an alpha-2 adrenergic agonist under development for the treatment of acute withdrawal from short-acting opioids. The study takes place in 2 parts: a 7-day inpatient double-blind treatment portion where subjects will be randomly assigned to one of three doses of study medication (2.4 mg total daily dose of lofexidine, 3.2 mg total daily dose of lofexidine, or placebo) followed by an optional open-label treatment period where subjects will be inpatient or outpatient and receive lofexidine at variable dosing for up to an additional 7 days. The Investigator hypothesizes that subjects will achieve maximum treatment effect with tolerable side effects at the 3.2 mg total daily dose and that both the 3.2 mg and 2.4 total daily doses will show better efficacy over placebo in treating symptoms of acute opioid withdrawal.
Conditions
- Opioid Dependence
- Acute Opioid Withdrawal Syndrome
Interventions
Lofexidine HClDrug
Lofexidine HCl tablets will be available in 0.2 mg tablets. Lofexidine will be provided in total daily doses as indicated during the double blind portion of the study.
PlaceboDrug
Lofexidine-matching tablets without the active pharmaceutical ingredient will be provided as 4 tablets QID during the double-blind portion of the study to subjects randomized to placebo.
Open Label Lofexidine HCLDrug
Lofexidine HCl tablets will are available in 0.2 mg tablets. During the optional open-label portion of the study, Lofexidine HCl can be prescribed at the discretion of the Investigator but total daily dose will not exceed 3.2 mg.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Difference Between the Overall Means From Short Opiate Withdrawal Scale of Gossop (SOWS-Gossop) ScoresTime frame: Days 1 through 7
Locations
18 sites in 1 country. Site status is shown where the registry gives one.
Site not named
Clovis, California
Site not named
Escondido, California
Site not named
San Diego, California
Site not named
Miami, Florida
Site not named
Orlando, Florida
Site not named
Atlanta, Georgia
Site not named
Oak Park, Illinois
Site not named
Lake Charles, Louisiana
Site not named
Baltimore, Maryland
Site not named
Flowood, Mississippi
Site not named
St Louis, Missouri
Site not named
Dayton, Ohio
Site not named
Mason, Ohio
Site not named
Austin, Texas
Site not named
Dallas, Texas
Site not named
DeSoto, Texas
Site not named
Orem, Utah
Site not named
Salt Lake City, Utah
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.